Abstract
Telling the story of the advances in chronic myeloid leukemia (CML), seen from a historical perspective, one cannot deny the extraordinary role of cytogenetics. When John Hughes Bennett and Rudolf Virchow reported what is thought to be the first descriptions of CML in 1845, nothing was known about the mechanism and the underlying genetics. Therefore, it was a quantum leap when the Philadelphia chromosome was discovered by Peter Nowel and David Hungerford in 1960 [1, 2]. By that time, they still used very basic chromosome staining techniques. The cells were grown on slides using short-term cell cultures [3], rinsed with tap water, and stained with Giemsa [4, 5]. Investigating acute leukemia they initially did not find consistent genetic abnormalities, but eventually they identified a characteristic small chromosome in two patients with CML. Together with other scientists like Paul Moorhead they were able to improve their preparation technique and report a series of seven patients all displaying a minute chromosome. In accordance with the Committee for the Standardization of Chromosomes, Tough and colleagues called this minute chromosome Philadelphia chromosome after the city it was first detected [4]. As cytogenetic techniques improved in the 1970s, Rowley discovered that the Philadelphia chromosome is the result of a translocation t(9;22)(q34;q11) between the long arms of chromosomes 9 and 22 with the derivative chromosome 22, der(22)t(9;22), being the Philadelphia chromosome [6]. de Klein et al. were then able to demonstrate that a small segment of chromosome 9 was translocated back to chromosome 22, providing evidence for the reciprocal nature of the translocation t(9;22) [7]. Later, Bartram and co-workers could show that the tyrosine kinase gene ABL1 (abelson) on chromosome 9 and the BCR (breakpoint cluster region) gene on chromosome 22 are fused and generate the BCR-ABL1 fusion gene on the Philadelphia chromosome [8–10]. This was the basis for the characterization of the BCR-ABL1 fusion protein, the development of the first BCR-ABL1 tyrosine kinase inhibitor (TKI) imatinib in 1996 and the success story of CML treatment [11–13]. Currently, the life expectancy of patients with newly diagnosed CML in chronic phase (CP) is very close to that of age-matched individuals [14, 15].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Deininger MW. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program. 2008:419–26.
Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science. 1960;132:1497.
Osgood EE, Kripphahne ML. The gradient tissue culture method. Exp Cell Res. 1955;9(1):116–27.
Nowell PC. Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest. 2007;117(8):2033–5.
Tough IM, WM CB, Baikie AG, Buckton KE, Harnden DG, Jacobs PA, King MJ, McBride JA. Cytogenetic studies in chronic myeloid leukaemia and acute leukaemia associated with monogolism. Lancet. 1961;1(7174):411–7.
Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290–3.
de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982;300(5894):765–7.
Balabanov S, Braig M, Brummendorf TH. Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. Drug Discov Today Technol. 2014;11:89–99.
Bartram CR, de KA, Hagemeijer A, van AT, Geurts van KA, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306(5940):277–80.
Groffen J, Stephenson JR, Heisterkamp N, de KA, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36(1):93–9.
Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112(13):4808–17.
Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian HM, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–17.
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561–6.
Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid Leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–7.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen J, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saussele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84. https://doi.org/10.1038/s41375-020-0776-2.
Prakash O, Yunis JJ. High resolution chromosomes of the t(9;22) positive leukemias. Cancer Genet Cytogenet. 1984;11(4):361–7.
Hiller B, Bradtke J, Balz H, Rieder H. CyDAS: a cytogenetic data analysis system. Bioinformatics. 2005;21(7):1282–3.
Gorusu M, Benn P, Li Z, Fang M. On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet. 2007;173(2):97–106.
Huret JL. Complex translocations, simple variant translocations and Ph-negative cases in chronic myelogenous leukaemia. Hum Genet. 1990;85(6):565–8.
Marzocchi G, Castagnetti F, Luatti S, Baldazzi C, Stacchini M, Gugliotta G, Amabile M, Specchia G, Sessarego M, Giussani U, Valori L, Discepoli G, Montaldi A, Santoro A, Bonaldi L, Giudici G, Cianciulli AM, Giacobbi F, Palandri F, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G, Testoni N. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA working party on CML analysis. Blood. 2011;117(25):6793–800.
O'Brien S, Thall PF, Siciliano MJ. Cytogenetics of chronic myelogenous leukaemia. Baillieres Clin Haematol. 1997;10(2):259–76.
Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107(2):76–94.
Fisher AM, Strike P, Scott C, Moorman AV. Breakpoints of variant 9;22 translocations in chronic myeloid leukemia locate preferentially in the CG-richest regions of the genome. Genes Chromosomes Cancer. 2005;43(4):383–9.
Potter AM, Watmore AE, Cooke P, Lilleyman JS, Sokol RJ. Significance of non-standard Philadelphia chromosomes in chronic granulocytic leukaemia. Br J Cancer. 1981;44(1):51–4.
De Braekeleer M. Variant Philadelphia translocations in chronic myeloid leukemia. Cytogenet Cell Genet. 1987;44(4):215–22.
Verma RS, Macera MJ. Genomic diversity of Philadelphia-positive chronic myelogenous leukemia. Leuk Res. 1987;11(9):833–42.
Yehuda O, Abeliovich D, Ben-Neriah S, Sverdlin I, Cohen R, Varadi G, Orr R, Ashkenazi YJ, Heyd J, Lugassy G, Ben YD. Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive. Cancer Genet Cytogenet. 1999;114(2):100–7.
El-Zimaity MM, Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D, Ferrajoli A, Hayes K, Nebiyou BB, Zhou X, Rios MB, Glassman AB, Cortes JE. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol. 2004;125(2):187–95.
Fabarius A, Leitner A, Hochhaus A, Muller MC, Hanfstein B, Haferlach C, Gohring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, Hehlmann R. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML study IV. Blood. 2011;118(26):6760–8.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84.
Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G, Trakhtenbrot L. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet. 2001;128(2):114–9.
Herens C, Tassin F, Lemaire V, Beguin Y, Collard E, Lampertz S, Croisiau C, Lecomte M, De PB, Longree L, Koulischer L. Deletion of the 5'-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients. Br J Haematol. 2000;110(1):214–6.
Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, Szer J, Prince HM, Turner P, Grace C, Nacheva EP, Green AR. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood. 2001;98(6):1732–8.
Kolomietz E, Al-Maghrabi J, Brennan S, Karaskova J, Minkin S, Lipton J, Squire JA. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submikroskopic deletions and may lead to altered prognosis. Blood. 2001;97(11):3581–8.
Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, Bench A, Champion K, Huntly B, Green AR. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood. 2000;95(3):738–43.
Reid AG, Huntly BJ, Grace C, Green AR, Nacheva EP. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol. 2003;121(3):419–27.
Huh J, Jung CW, Kim JW, Kim HJ, Kim SH, Shin MG, Kim YK, Kim HJ, Suh JS, Moon JH, Sohn SK, Nam GH, Lee JE, Kim DH. Genome-wide high density single-nucleotide polymorphism array-based karyoty** improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia. Ann Hematol. 2011;90(11):1255–64.
Kreil S, Pfirrmann M, Haferlach C, Waghorn K, Chase A, Hehlmann R, Reiter A, Hochhaus A, Cross NC. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood. 2007;110(4):1283–90.
Castagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini M, Kerim S, Giugliano E, Albano F, Cuneo A, Abruzzese E, Martino B, Palandri F, Amabile M, Iacobucci I, Alimena G, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML working party analysis. J Clin Oncol. 2010;28(16):2748–54.
Huntly BJP, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C, Byrne J, Brizard A, Niederwieser D, Freeman-Edward J, Cuthbert G, Bown N, Clark RE, Nacheva EP, Green AR, Deininger MW. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood. 2003;102(6):2205–12.
Quintas-Cardama A, Kantarjian H, Shan J, Jabbour E, Abruzzo LV, Verstovsek S, Garcia-Manero G, O'Brien S, Cortes J. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer. 2011;117(22):5085–93.
Luatti S, Baldazzi C, Marzocchi G, Ameli G, Bochicchio MT, Soverini S, Castagnetti F, Tiribelli M, Gugliotta G, Martinelli G, Baccarani M, Cavo M, Rosti G, Testoni N. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. Oncotarget. 2017;8(18):29906–13. https://doi.org/10.18632/oncotarget.15369.
Pelz AF, Kroning H, Franke A, Wieacker P, Stumm M. High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements. Ann Hematol. 2002;81(3):147–53.
Virgili A, Brazma D, Reid AG, Howard-Reeves J, Valganon M, Chanalaris A, De MV, Marin D, Apperley JF, Grace C, Nacheva EP. FISH map** of Philadelphia negative BCR/ABL1 positive CML. Mol Cytogenet. 2008;1:14.
Heim S, Mitelman F. Cancer cytogenetics: chromosomal and molecular genetic aberrations of tumor cells. 4th ed. Chichester: Wiley Blackwell; 2015.
Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101(10):3794–800.
Anastasi J, Feng J, Le Beau MM, Larson RA, Rowley JD, Vardiman JW. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia. 1995;9(4):628–33.
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb H-J, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Burchert A, Brümmendorf TH, Hasford J, Hochhaus A, Saußele S, Baccarani M, von Weikersthal LF, Hahn M, Schlimok G, Reichert D, Janssen J, Martens U, Majunke P, Reichert P, Neben K, Korsten S, Scholz C, Oldenkott B, Heßling J, Kingreen D, Sperling C, Schelenz C, Blau I, Urmersbach A, Ludwig W, Le Coutre P, Arnold R, de Wit M, Pezzutto A, Schäfer E, Schroers R, Lochter A, Behringer D, Ko Y, Weidenhöfer S, Verbeek W, Brossart P, Trenn G, Pommerien W, Krauter J, Doering G, Munzinger H, Diekmann C, Hertenstein B, Stier S, Möller-Faßbender F, Hänel M, Zöller T, Lamberti C, Koch B, Henzel A, Wagner S, Schmalenbach A, Hoffknecht M, Ehninger G, Kiani A, Illmer T, Aul C, Flaßhove M, Henneke F, Simon M, Müller L, Becker H, Janz R, Eckart MJ, Fuchs R, Schlegel F, Wattad M, Rudolph R, Beelen DW, Lindemann A, Linck D, Wassman JE, Al-Batran S, Reiber T, Waller CF, Hoeffkes H, Schulz L, Tajrobehkar K, Mittermüller J, Pralle H, Runde V, Hoyer A, Tessen H, Trümper L, Schmidt C, Sieber M, Eschenburg H, Depenbusch R, Rösel S, Lindemann HW, Wolf H, Spohn C, Moeller R, Hossfeld D, Zander A, Schafhausen P, Köster H, Hollburg W, Schmitz N, Dürk H, Hemeier M, Grote-Metke A, Weischer H, Bechtel B, Balleisen L, Sosada M, Ho A, Petersen V, Dengler J, Bildat S, Hahn L, Dietzfelbinger H, Gröschel W, Bartholomäus A, Freier W, Sievers B, Pfreundschuh IM, Herrmann T, Fauser A, Menzel J, Kemmerling M, Hansen R, Link H, Schatz M, Bentz M, Prümmer O, Kneba M, Heymanns J, Schmitz S, Scheid C, Lollert A, Neise M, Planker M, Stauch M, Schröder M, Kempf B, Vehling-Kaiser U, Kremers S, Köchling G, Müller L, Hartmann F, Neuhaus T, Fetscher S, Kämpfe D, Heil G, Uppenkamp M, Goldmann B, Huber TF, Hieber U, Plöger C, Griesshammer M, Lange C, Göttler B, Lunscken C, Schiel X, Scheidegger C, Stötzer O, Hitz H, Schick H, Völkl S, Spiekermann K, Berdel W, Hebart H, Ladda E, Schmidt P, Burkhardt U, Hentschke S, Falge C, Reschke D, Köhne CA, Müller-Naendrup C, Sauer M, Frühauf S, Ranft K, Dencausse Y, Sandritter B, Baake G, Hofknecht M, Dengler R, Edinger M, Schenk M, Wehmeier A, Weidelich HP, Pihusch R, Stahlhut K, Baldus M, Matzdorff A, Geer T, Schanz S, Käfer G, Gassmann W, Priebe-Richter C, Demandt M, Springer G, Fiechtner H, Denzlinger C, Schleicher J, Assman D, Gaeckler R, Adam G, Waladkhani A, Rendenbach B, Forstbauer H, Kanz L, Jacki S, Stegelmann F, Kalhori N, Nusch A, Langer W, Müller F, Brettner S, Uebelmesser B, Kamp T, Schadeck-Gressel C, Josten K, Klein O, Schwerdtfeger R, Baurmann H, Strotkötter H, Fett W, Raghavachar A, Maintz C, Goebler MC, Schlag R, Elsel W, Wernli M, Heim D, Wuillemin W, Hess U, Gmür J, Mayer J, for the S, the German CMLSG. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020; https://doi.org/10.1038/s41375-020-0826-9.
Gong Z, Medeiros LJ, Cortes JE, Chen Z, Zheng L, Li Y, Bai S, Lin P, Miranda RN, Jorgensen JL, McDonnell TJ, Wang W, Kantarjian HM, Hu S. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Adv. 2017;1(26):2541–52.
Hagemeijer A, Stenfert Kroeze WF, Abels J. Cytogenetic follow-up of patients with nonlymphocytic leukemia I. Philadelphia chromosome-positive chronic myeloid leukemia. Cancer Genet Cytogenet. 1980;2(4):317–26.
Mitelman F, Levan G, Nilsson PG, Brandt L. Non-random karyotypic evolution in chronic myeloid leukemia. Int J Cancer. 1976;18(1):24–30.
Fioretos T, Strombeck B, Sandberg T, Johansson B, Billstrom R, Borg A, Nilsson PG, van den Berghe H, Hagemeijer A, Mitelman F, Höglund M. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. Blood. 1999;94(1):225–32.
Coyle T, Najfeld V. Translocation (3;21) in Philadelphia chromosome-positive chronic myelogenous leukemia prior to the onset of blast crisis. Am J Hematol. 1988;27(1):56–9.
Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer (2021). Mitelman F, Johansson B and Mertens F (Eds.), https://mitelmandatabase.isb-cgc.org.
Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, McDonnell TJ, Ok CY, Kantarjian HM, Medeiros LJ, Hu S. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 2015a;126(14):1699–706.
Chen Z, Shao C, Wang W, Zuo Z, Mou X, Hu SJ, DiGiuseppe JA, Zu Y, Medeiros LJ, Hu S. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2017;31(3):585–92. https://doi.org/10.1038/leu.2016.231.
Ferro MT, Steegman JL, Escribano L, Heiurichs B, Parada L, Garcia-Sagredo JM, Resino M, Cabello P, San RC. Ph-positive chronic myeloid leukemia with t(8;21)(q22;q22) in blastic crisis. Cancer Genet Cytogenet. 1992;58(1):96–9.
Heim S, Christensen BE, Fioretos T, Sorensen AG, Pedersen NT. Acute myelomonocytic leukemia with inv(16)(p13q22) complicating Philadelphia chromosome positive chronic myeloid leukemia. Cancer Genet Cytogenet. 1992;59(1):35–8.
Pintado T, Ferro MT, San RC, Mayayo M, Larana JG. Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer. 1985;55(3):535–41.
Rubin CM, Larson RA, Bitter MA, Carrino JJ, Le Beau MM, Diaz MO, Rowley JD. Association of a chromosomal 3;21 translocation with the blast phase of chronic myelogenous leukemia. Blood. 1987;70(5):1338–42.
Wang W, Tang G, Cortes JE, Liu H, Ai D, Yin CC, Li S, Khoury JD, Bueso-Ramos C, Medeiros LJ, Hu S. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol. 2015c;8:32.
Yin CC, Medeiros LJ, Glassman AB, Lin P. T(8;21)(q22;q22) in blast phase of chronic myelogenous leukemia. Am J Clin Pathol. 2004;121(6):836–42.
Hoehn D, Lu G, Konoplev S, Zhou Y, Bueso-Ramos CE, Zuo Z, Hsu B, Medeiros LJ, Yin CC. t(15;17)(q24.1;q21.2)/PML-RARA in blast phase of chronic myelogenous leukemia: a rare form of clonal evolution. J Hematop. 2013;6(4):187–93.
Bernstein R, Morcom G, Pinto MR, Mendelow B, Dukes I, Penfold G, Bezwoda W. Cytogenetic findings in chronic myeloid leukemia (CML); evaluation of karyotype, blast morphology, and survival in the acute phase. Cancer Genet Cytogenet. 1980;2(1):23–37.
Andersson A, Olofsson T, Lindgren D, Nilsson B, Ritz C, Eden P, Lassen C, Rade J, Fontes M, Morse H, Heldrup J, Behrendtz M, Mitelman F, Hoglund M, Johansson B, Fioretos T. Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. Proc Natl Acad Sci U S A. 2005;102(52):19069–74.
Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, Liu HC, Mahfouz R, Raimondi SC, Lenny N, Patel A, Downing JR. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102(8):2951–9.
Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA, Bloomfield CD, de la Chapelle A, Krahe R. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci U S A. 2001;98(3):1124–9.
Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer. 2005;43(3):227–38.
Schütte J, Opalka B, Becher R, Bardenheuer W, Szymanski S, Lux A, Seeber S. Analysis of the p53 gene in patients with isochromosome 17q and Ph1-positive or -negative myeloid leukemia. Leuk Res. 1993;17(6):533–539.
Rege-Cambrin G, Gaidano G, Serra A, Scaravaglio P, Guglielmelli T, Guerrasio A, Giovinazzo B, Saglio G. Analysis of the p53 gene in myeloid malignancies associated with chromosomal abnormalities involving the short arm of chromosome 17. Leukemia. 1994;8 Suppl 1:S23–6.
Collins SJ, Groudine MT. Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis. Blood. 1987;69(3):893–8.
Al-Achkar W, Wafa A, Ikhtiar A, Liehr T. Three-way Philadelphia translocation t(9;10;22)(q34;p11.2;q11.2) as a secondary abnormality in an imatinib mesylate-resistant chronic myeloid leukemia patient. Oncol Lett. 2013;5(5):1656–8.
Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Maier-Dobersberger T, Greinix H, Mannhalter C, Haas OA, Lechner K, Lion T. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood. 1995;86(6):2371–8.
Andrews DF III, Collins SJ. Heterogeneity in expression of the bcr-abl fusion transcript in CML blast crisis. Leukemia. 1987;1(10):718–24.
Ogawa S, Kurokawa M, Tanaka T, Tanaka K, Hangaishi A, Mitani K, Kamada N, Yazaki Y, Hirai H. Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia. 1996;10(5):788–94.
Roche-Lestienne C, Deluche L, Corm S, Tigaud I, Joha S, Philippe N, Geffroy S, Lai JL, Nicolini FE, Preudhomme C. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood. 2008;111(7):3735–41.
Preudhomme C, Warot-Loze D, Roumier C, Grardel-Duflos N, Garand R, Lai JL, Dastugue N, MacIntyre E, Denis C, Bauters F, Kerckaert JP, Cosson A, Fenaux P. High incidence of biallelic point mutations in the runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood. 2000;96(8):2862–9.
Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019;33(8):1835–50. https://doi.org/10.1038/s41375-019-0512-y.
Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S, Schnittger S, Kern W, Muller MC, Hochhaus A, Haferlach T, Haferlach C. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25(3):557–60.
Haferlach C, Bacher U, Schnittger S, Weiss T, Kern W, Haferlach T. Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment. Leukemia. 2010;24(3):638–40.
Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, Gohring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, Hanel M, Kohne CH, Lindemann HW, Berdel WE, Staib P, Muller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Brummendorf TH, Edinger M, Hofmann WK, Pfirrmann M, Hasford J, Krause S, Hochhaus A, Saussele S, Hehlmann R. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol. 2015;94(12):2015–24.
Wang W, Cortes JE, Lin P, Khoury JD, Ai D, Tang Z, Tang G, Jorgensen JL, Medeiros LJ, Hu S. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2015b;29(11):2263–6.
Guttenbach M, Koschorz B, Bernthaler U, Grimm T, Schmid M. Sex chromosome loss and aging: in situ hybridization studies on human interphase nuclei. Am J Hum Genet. 1995;57(5):1143–50.
Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 2010;116(11):2673–81.
Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, DiGiuseppe JA, Chen Z, Kantarjian HM, Medeiros LJ, Hu S. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016;127(22):2742–50. https://doi.org/10.1182/blood-2016-01-690230.
Ariyama T, Inazawa J, Uemura Y, Kakazu N, Maekawa T, Urase F, Irimajiri K, Horiuchi A, Nakamura Y, Abe T. Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of alpha-interferon therapy for Ph positive chronic myelocytic leukemia. Cancer Genet Cytogenet. 1995;81(1):20–3.
Fayad L, Kantarjian H, O'Brien S, Seong D, Albitar M, Keating M, Talpaz M. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia. 1997;11(5):767–71.
Bacher U, Hochhaus A, Berger U, Hiddemann W, Hehlmann R, Haferlach T, Schoch C. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia. 2005;19(3):460–3.
Bumm T, Muller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E, Leiblein S, Franke C, Hennig E, Friedrich T, Krahl R, Niederwieser D, Deininger MW. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood. 2003;101(5):1941–9.
Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003;101(11):4611–4.
Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood. 2017;130(19):2084–91. https://doi.org/10.1182/blood-2017-07-792143.
Medina J, Kantarjian HM, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Rios MB, Hayes K, Cortes J. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer. 2003;98(9):1905–11.
Meeus P, Demuynck H, Martiat P, Michaux L, Wouters E, Hagemeijer A. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib. Leukemia. 2003;17(2):465–7.
Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R, Hiddemann W, Hochhaus A. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia. 2003;17(2):461–3.
Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C, Mozziconacci MJ, Maarek O, Mossafa H, Auger N, Dastugue N, Talmant P, Van Den AJ, Leonard C, N'Guyen KF, Mugneret F, Viguie F, Lafage-Pochitaloff M, Bastie JN, Roux GL, Nicolini F, Maloisel F, Vey N, Laurent G, Recher C, Vigier M, Yacouben Y, Giraudier S, Vernant JP, Salles B, Roussi J, Castaigne S, Leymarie V, Flandrin G, Lessard M. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia. 2004;18(8):1340–6.
Kantarjian HM, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker BJ, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Loughran TP, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645–52.
O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, Braziel RM. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 2003;17(3):481–7.
Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjian HM, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, Druker BJ, Guilhot F. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer. 2007;110(7):1509–19.
Schnittger S, Kuznia S, Meggendorfer M, Nadarajah N, Jeromin S, Alpermann T, Roller A, Albuquerque A, Weissmann S, Ernst T, Eder C, Dicker F, Kern W, Kohlmann A, Haferlach T, Hochhaus A, Haferlach C. Tyrosine kinase inhibitor treated CML patients Harboring Philadelphia-negative cytogenetically aberrant clones show molecular mutations in 31% of cases not present at diagnosis: a high-throughput amplicon sequencing study of 29 genes. Blood. 2013;122(21):611a.
Schnittger S, Meggendorfer M, Nadarajah N, Alpermann T, Kern W, Haferlach T, Haferlach C. In CML patients with good response to TKIs other gene mutations are frequently (37%) present in addition to Philadelphia negative, cytogenetically aberrant clones but are rare (4%) in cases with MMR and normal karyotype. Blood. 2014;124(21):3126a.
Wang JY. Regulation of cell death by the Abl tyrosine kinase. Oncogene. 2000;19(49):5643–50.
Groves MJ, Sales M, Baker L, Griffiths M, Pratt N, Tauro S. Factors influencing a second myeloid malignancy in patients with Philadelphia-negative −7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer Genet. 2011;204(1):39–44.
Bidet A, Dulucq S, Smol T, Marceau-Renaut A, Morisset S, Coiteux V, Noel-Walter MP, Nicolini FE, Tigaud I, Luquet I, Struski S, Gaillard B, Penther D, Tondeur S, Nadal N, Hermet E, Veronese L, Rea D, Gervais C, Theisen O, Terre C, Cony-Makhoul P, Lefebvre C, Gaillard JB, Radford I, Vervaeke AL, Barin C, Chapiro E, Nguyen-Khac F, Etienne G, Preudhomme C, Mahon FX, Roche-Lestienne C. Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia. Haematologica. 2019;104(6):1150–5. https://doi.org/10.3324/haematol.2018.208801.
Testoni N, Marzocchi G, Luatti S, Amabile M, Baldazzi C, Stacchini M, Nanni M, Rege-Cambrin G, Giugliano E, Giussani U, Abruzzese E, Kerim S, Grimoldi MG, Gozzetti A, Crescenzi B, Carcassi C, Bernasconi P, Cuneo A, Albano F, Fugazza G, Zaccaria A, Martinelli G, Pane F, Rosti G, Baccarani M. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood. 2009;114(24):4939–43.
Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, Schlegelberger B, Saussele S, Dietz CT, Erben P, Hehlmann R, Hasford J, Hochhaus A, Muller MC. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol. 2014;140(11):1965–9.
Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova PK, Dulucq S, Martinelli G, Oppliger LE, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, Muller MC, Hochhaus A. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29(5):999–1003.
Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172–5.
Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35.
Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Rea D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424–30.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Balk, B., Fabarius, A., Haferlach, C. (2021). Cytogenetics of Chronic Myeloid Leukemia (CML). In: Hehlmann, R. (eds) Chronic Myeloid Leukemia. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-71913-5_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-71913-5_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-71912-8
Online ISBN: 978-3-030-71913-5
eBook Packages: MedicineMedicine (R0)